Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$235.26
+3.1%
$237.45
$96.09
$260.19
$11.75B0.61.16 million shs482,593 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.56
+1.7%
$23.56
$13.39
$27.72
$12.56B1.684.24 million shs4.62 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$28.43
+1.3%
$26.03
$8.84
$31.74
$3.53B0.81.48 million shs801,994 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.47
+1.1%
$15.63
$12.55
$30.98
$11.88B-1.264.48 million shs3.04 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+3.06%-5.81%-7.80%+27.73%+109.44%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.73%+3.74%+5.65%+9.85%+71.82%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+1.07%-6.51%+19.19%+19.97%+194.43%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+1.11%-2.58%+10.42%-26.75%-39.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$235.26
+3.1%
$237.45
$96.09
$260.19
$11.75B0.61.16 million shs482,593 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.56
+1.7%
$23.56
$13.39
$27.72
$12.56B1.684.24 million shs4.62 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$28.43
+1.3%
$26.03
$8.84
$31.74
$3.53B0.81.48 million shs801,994 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.47
+1.1%
$15.63
$12.55
$30.98
$11.88B-1.264.48 million shs3.04 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+3.06%-5.81%-7.80%+27.73%+109.44%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.73%+3.74%+5.65%+9.85%+71.82%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+1.07%-6.51%+19.19%+19.97%+194.43%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+1.11%-2.58%+10.42%-26.75%-39.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.95
Moderate Buy$259.0510.11% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.5511.68% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.58
Moderate Buy$35.1023.47% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.44
Hold$26.9774.36% Upside

Current Analyst Ratings Breakdown

Latest RCUS, ELAN, AXSM, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
7/7/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$302.00 ➝ $304.00
6/29/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Reiterated RatingOverweight
6/18/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$31.00 ➝ $32.00
6/17/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$275.00 ➝ $300.00
6/15/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeStrong-Buy
6/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$380.00
6/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeReduceOverweight
6/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy
6/4/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Initiated CoverageOutperform$46.00
6/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingOverweight
(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M18.96N/AN/A$1.75 per share134.43
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.71$2.36 per share10.83$13.18 per share1.94
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$247M14.47N/AN/A$5.84 per share4.87
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A50.38N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A20.951.64-4.95%7.42%3.66%8/5/2026 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)

Latest RCUS, ELAN, AXSM, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.26N/AN/AN/A$0.11 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.27N/AN/AN/A$1.31 billionN/A
8/5/2026Q2 2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.8912N/AN/AN/A$22.22 millionN/A
8/3/2026Q2 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.8575N/AN/AN/A$221.62 millionN/A
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/5/2026Q1 2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
5/1/2026Q1 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.19
4.04
4.04
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
7.41
7.41

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500125.77 million113.70 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110776.16 million128.07 millionOptionable

Recent News About These Companies

SMMT Stock Price Prediction
Why is SMMT stock tumbling today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$235.26 +6.98 (+3.06%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$230.77 -4.49 (-1.91%)
As of 07:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$25.56 +0.42 (+1.67%)
Closing price 07/14/2026 03:59 PM Eastern
Extended Trading
$25.58 +0.03 (+0.10%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$28.43 +0.36 (+1.27%)
Closing price 07/14/2026 03:59 PM Eastern
Extended Trading
$28.29 -0.14 (-0.48%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$15.47 +0.17 (+1.11%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$15.64 +0.17 (+1.07%)
As of 07:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.